Benjamin Burnett
Stock Analyst at Wells Fargo
(3.39)
# 964
Out of 5,072 analysts
86
Total ratings
53.23%
Success rate
2.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Maintains: Equal-Weight | $20 → $23 | $21.49 | +4.70% | 3 | Nov 20, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $29.08 | +20.36% | 3 | Nov 13, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $42 → $37 | $29.58 | +25.08% | 3 | Nov 13, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $163 → $157 | $151.50 | +3.63% | 2 | Nov 4, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.14 | +163.16% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $53.47 | -8.36% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $72.65 | +67.93% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $25.33 | +172.40% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $35.58 | +91.12% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.46 | +215.07% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $14.82 | +287.99% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $5.44 | +14,238.24% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $16 | $7.76 | +106.19% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $5.35 | +49.53% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $17.48 | +31.58% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $85.99 | +8.15% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $44 | $44.72 | -1.61% | 2 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $486.12 | -12.98% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $77.76 | -17.70% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $93.25 | +0.80% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $2.19 | +82.65% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.83 | +161.10% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.47 | +912.15% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $65.21 | +452.06% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.46 | +3,370.72% | 1 | Jan 6, 2021 |
Avadel Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $21.49
Upside: +4.70%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $29.08
Upside: +20.36%
Alkermes
Nov 13, 2025
Maintains: Overweight
Price Target: $42 → $37
Current: $29.58
Upside: +25.08%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $163 → $157
Current: $151.50
Upside: +3.63%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.14
Upside: +163.16%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $53.47
Upside: -8.36%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $72.65
Upside: +67.93%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $25.33
Upside: +172.40%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $35.58
Upside: +91.12%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.46
Upside: +215.07%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $14.82
Upside: +287.99%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $5.44
Upside: +14,238.24%
Nov 11, 2025
Maintains: Overweight
Price Target: $18 → $16
Current: $7.76
Upside: +106.19%
Nov 11, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $5.35
Upside: +49.53%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $17.48
Upside: +31.58%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $85.99
Upside: +8.15%
Nov 4, 2025
Maintains: Overweight
Price Target: $48 → $44
Current: $44.72
Upside: -1.61%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $486.12
Upside: -12.98%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $77.76
Upside: -17.70%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $93.25
Upside: +0.80%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $2.19
Upside: +82.65%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.83
Upside: +161.10%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.47
Upside: +912.15%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $65.21
Upside: +452.06%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.46
Upside: +3,370.72%